Menu Back toSession-5-Biosimilars-in-Practice-Critical-Market-Opportunities-Awaiting-to-be-Seized

Biosimilars Conference

Session 5: Biosimilars in Practice – Critical Market Opportunities Awaiting to be Seized

Session Chair(s)

Erika  Satterwhite

Erika Satterwhite

  • Head of Global Biosimilars Policy
  • Mylan, United States
The US biologic payer and reimbursement framework has presented challenges for a biologic multi-source market, with a number of barriers blocking meaningful utilization and update. This session focuses on identifying mechanisms to overcome market access barriers in the US and build a suitable environment to release the untapped potential of biosimilar medicines competition.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Appraise the impact of market barriers on biosimilar use in the US in 2019
  • Illustrate, by case studies, the impact on clinical use of biosimilars of common contracting features
  • Identify concrete policy solutions which, when implemented, can deliver the most significant improvement in creating a functioning US biosimilars market


Juliana Marguerite Reed, MS

US Biosimilar Industry Perspective

Juliana Marguerite Reed, MS

  • Vice President, Corporate Affairs, Global I & I and Biosimilars Lead
  • Pfizer, Inc., United States
Murray  Aitken

Global Perspective 2030 on Biosimilars

Murray Aitken

  • Senior Vice President and Executive Director
  • IQVIA, United States
Elizabeth  Jex


Elizabeth Jex

  • Attorney Advisor, Office of Policy Planning
  • Federal Trade Commission, United States

Contact us

Registration Questions?

Send Email

Check out our 2019 Program!